// App-Quantinova.ai

TCT-262 : Comparable low rates of MACE between patients with ST-segment elevation myocardial infarction (STEMI) and non-STEMI (NSTEMI) patients in the 12-month follow-up of the e-BioMatrix registry

Researchers

Presenter

  • Mariano Valdes

Principal Investigators

  • Keith G. Oldroyd

  • Ian Menown

  • Franz Eberli

  • Imad A. Alhaddad

  • Marco Roffi

  • David Hildick-Smith

  • David G. Iosseliani

  • jacques berland

  • Franz X. Kleber

  • Philip Urban

Medical Centers

  • Jordan Hospital, Amman, Jordan

  • HOPITAUX UNIVERSITAIRES DE GENEVE (HUG), Geneva, Switzerland

  • University of Glasgow, Glasgow, United Kingdom

  • Hospital Clinico Universitario Virgen de la Arrixaca, Murcia, Spain

  • Clinique Saint Hilaire, Rouen, France

  • Craigavon Area Hospital, Craigavon, United Kingdom

  • Hopital de la Tour, Geneva, Switzerland

  • Royal Sussex County Hospital, Brighton, United Kingdom

  • Oncology, Triemli Hospital Zurich, Zurich, Switzerland

  • Brustzentrum Charite-Universitatsmedizin, Berlin, Germany

Locations

  • Spain

  • Germany

  • Switzerland

  • United Kingdom

  • Jordan

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Coronary Artery Disease

  • Venous thrombosis

  • Stable coronary artery disease

Biomarkers

  • N/A

Drug/Treatment

  • Biolimus A9

  • Umirolimus

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved